23 developments in spine & orthopedic biologics research in 2018


Here are 23 study developments in spine and orthopedic biologics for 2018 so far:

1. Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics and Sports Medicine reported positive results in a study to regenerate knee cartilage through stem cell injections.

2. Regenerative medicine company Orthocell successfully conducted a pre-clinical evaluation using CelGro collagen rope for ACL reconstruction.

3. SpinalCyte completed the first double-blind, placebo-controlled human trial using CybroCell, a human dermal fibroblast injection to treat degenerative disc disease.

4. Bone Therapeutics finished patient recruitment for its Phase IIA lumbar spinal fusion study.

5. The first patient in Centrexion Therapeutics' Phase 3 VICTORY-1 clinical trial was givenCNTX-4975, a synthetic trans-capsaicin injection for the treatment of chronic moderate to severe pain due to knee osteoarthritis.

6. Researchers grafted human spinal cord-derived neural progenitor cells into cervical spinal cord injury sites in rhesus monkeys in a study in Nature Medicine.

7. The use of biologics before and during pregnancy is not associated with an increased risk of preterm delivery or small-for-gestational-age births, a study in Annals of the Rheumatic Diseases found.

8. Gregory Lutz, MD, and Kevin Pauza, MD, launched a study to examine the clinical effectiveness of Discseel, a biologic treatment to restore and regrow damaged discs in the spine.

9. Cerapedics received FDA approval to initiate a study of P-15L Peptide Enhanced Bone Graft against autografts in transforaminal lumbar interbody fusion surgery for degenerative disc disease.

10. Greg Merrell, MD, treated the first U.S. patient in Cartiva's GRIP 2 study to treat osteoarthritis of the thumb.

11. DiscGenics presented results from two preclinical studies assessing its IDCT product, a homologous, allogenic, injectable cell therapy.

12. Mesoblast completed enrollment for its Phase 3 mesenchymal cell therapy trial to treat chronic low back pain due to degenerative disc disease.

13. A new class of clay nanoparticles can lead human mesenchymal stem cells to develop into bone or cartilage cells according to findings in the Proceedings of the National Academy of Sciences of the United States of America.

14. Plano-based Texas Back Institute researchers are assessing the effectiveness of stem cells for revitalizing spinal tissue in a clinical trial.

15. Domagoj Coric, MD, treated the first patient in the phase 1/2 U.S. clinical trial testing DiscGenics' IDCT for treating degenerative disc disease.

16. Transplanted human spinal cord-derived neural stem cells may stabilize functioning in amyotrophic lateral sclerosis patients, according to a study in the Annals of Clinical and Translational Neurology.

17. Researchers successfully grafted induced pluripotent, stem cell-derived, neural precursor cells into the spinal cords of pigs with and without spinal cord injury with only temporary immunosuppression, according to a study in Science Translational Medicine.

18. Osteoarthritis-mesenchymal stem cells may drive cartilage degeneration pathogenesis and should be targeted in osteoarthritis therapy, according to a study in Scientific Reports.

19. Mikkel O. Andersen, MD, of Middelfart Hospital in Denmark, reported results from the IVANOS study investigating Cerapedics' i-FACTOR Peptide Enhanced Bone Graft.

20. Treating knee arthritis with NASHA (durolane hyaluronic acid) is a safe and effective procedure, according to a study in Open Access Rheumatology: Research and Reviews.

21. A first-in-human phase 1 clinical trial, which neural stem cells were transplanted into chronic spinal cord injury patients, improved motor and sensory function in three of four subjects with no adverse effects, according to results published in Cell Stem Cell.

22. The University Medical Center Utrecht in the Netherlands will begina study comparing Kuros Biosciences' MagnetOs with autologous bone in posterolateral spinal fusion.

23. Adipose-derived autologous stem cell therapy may be used to successfully repair a meniscus injury, according to a study in the Journal of Medical Cases.

More articles on biologics:

3 things to know about AlloSource

Aziyo Biologics enters co-marketing agreement with SurGenTec for minimally invasive bone graft delivery: 3 insights

Cerapedics closes $22M financing round: 3 takeaways

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers